Ignite Creation Date:
2024-05-06 @ 3:27 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04639622
Status:
RECRUITING
Last Update Posted:
2022-02-11
First Post:
2019-04-26
Brief Title:
GENetic Fronto Temporal Dementia Initiative in Lille
Sponsor:
University Hospital Lille
Organization:
University Hospital Lille
Study Overview
Official Title:
GENetic Fronto Temporal Dementia Initiative in Lille
Status:
RECRUITING
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GENFI-LILLE
Brief Summary:
GENFI Lille is a French cohort that belongs to the international initiative GENFI2 a five year longitudinal biomarker cohort study of genetic FTD and its associated disorders including MNDALS investigating members of families with a known mutation in GRN or MAPT or an expansion in C9orf72 including those affected with the disorder as well as at-risk members of families
Detailed Description:
The purposes of this study is
to improve characterization of symptomatic FTD patients or presymptomatic subjects at risk of genetic FTD
to develop markers indicative of the optimal time to start disease-modifying therapy based on the proximity to clinical onset
to develop markers of disease progression that can be used as outcome measures
to derive sample size estimates for clinical trials
Participants will include those affected with the disorder as well as at-risk members of families both mutation carriers and non-carrier first-degree relatives who will serve as a control group
All participants will be assessed longitudinally with a set of clinical neuropsychiatric cognitive imaging and biosample protocols
to improve characterization of symptomatic FTD patients or presymptomatic subjects at risk of genetic FTD
to develop markers indicative of the optimal time to start disease-modifying therapy based on the proximity to clinical onset
to develop markers of disease progression that can be used as outcome measures
to derive sample size estimates for clinical trials
Participants will include those affected with the disorder as well as at-risk members of families both mutation carriers and non-carrier first-degree relatives who will serve as a control group
All participants will be assessed longitudinally with a set of clinical neuropsychiatric cognitive imaging and biosample protocols
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-A02579-46 | OTHER | ID-RCB | None |